Moreover, PARP1 was a prognostic biomarker for poor clinical outcomes in breast cancer patients [56]; therefore, PARP1 inhibitors were extensively studied as a promising class of anticancer agents [57]. The gene discussed is PARP1; the disease is breast cancer.